InvestorsHub Logo
Post# of 100917
Next 10

MWM

Followers 1063
Posts 141593
Boards Moderated 14
Alias Born 03/31/2006

MWM

Re: EdF post# 82732

Friday, 05/22/2020 6:12:10 PM

Friday, May 22, 2020 6:12:10 PM

Post# of 100917
EVFM sounds like the perfect trade for you buddy!

U.S. FDA Approves Evofem Biosciences' Phexxi (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy


Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company's product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.